The Medical Foods For Inborn Errors Of Metabolism Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Medical Foods For Inborn Errors Of Metabolism Market:
According to The Business Research Company’s Medical Foods For Inborn Errors Of Metabolism Global Market Report 2024, The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $2.72 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to global health initiatives, increased recognition of nutritional therapies, precision medicine approaches, increasing incidence of metabolic disorders, personalized digital nutrition platforms.
The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $4.83 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to telehealth integration, rising demand for clean label products, expanded newborn screening programs, patient-centric care models, plant-based and sustainable formulations. Major trends in the forecast period include technological advancements in genetic testing, advancements in food processing technologies, innovations in ingredient technology, technological advancements in food formulation.
The rise in genetic (inherited) disorders is expected to propel the growth of medical foods for inborn errors in the metabolism market going forward. Genetic (inherited) disorders refer to a disease that is entirely or partially brought on by a deviation from the typical DNA sequence. Medical foods are essential for infants with metabolic abnormalities to deliver specialized nutrition created to address the unique metabolic requirements of people with these illnesses, thereby assisting in the prevention of nutritional deficits and metabolic needs for promoting their growth and well-being. For instance, in May 2021, according to Medline Plus, a US-based online information service produced by the United States National Library of Medicine, the incidence of a gene variant each year in the United States diagnoses 1 in 200,000 individuals with syndrome A. Around the world, 15,000 patients with syndrome B have been diagnosed. Therefore, the rise in genetic (inherited) disorders is driving the growth of medical foods for inborn errors of metabolism market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12161&type=smp
The medical foods for inborn errors of metabolism market covered in this report is segmented –
1) By Product: Amino Acid, Glytactin with GMP Amino Acid-Modified Infant Formula with Iron, Low-Calcium/Vitamin D-Free Infant Formula with Iron, Low Protein Food, Other Products
2) By Diseases: Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I Renal Disease, Other Diseases
3) By Age Group: Infants, Weaning, Adolescent, Adults
4) By Forms: Powder, Liquids, Gels, Other Forms
5) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Drugs Stores, Online Pharmacies, Other Distribution Channels
Product innovation has emerged as a key trend gaining popularity in medical food for inborn errors in the metabolism market. Major companies operating in medical food for inborn errors in the metabolism market are concentrating on creating innovative products to strengthen their position in the market. For instance, in December 2021, SFI Health, a Switzerland-based natural healthcare company introduced EQUAZEN PRO, a specially formulated medical food for the dietary treatment of a disease or condition with specific nutritional requirements for omega fatty acid levels. EQUAZEN PRO promotes healthy fatty acid metabolism and helps to restore omega-heavy acid levels. EQUAZEN PRO is scientifically proven to improve brain health for children and adolescents with ADHD and associated neurodiverse diseases to offer nutritional assistance. It contains sustainably obtained fish oils and evening primrose oil, and the capsule shell composition guarantees gastro resistance, delaying the transfer of fish oil from the stomach to the intestine and avoiding probable fishy flavor or reflux.
The medical foods for inborn errors of metabolism market report table of contents includes:
1. Executive Summary
2. Medical Foods For Inborn Errors Of Metabolism Market Characteristics
3. Medical Foods For Inborn Errors Of Metabolism Market Trends And Strategies
4.Medical Foods For Inborn Errors Of Metabolism market analysis
5.Medical Foods For Inborn Errors Of Metabolism Market Size And Growth
6.Medical Foods For Inborn Errors Of Metabolism Segmentation
7.Medical Foods For Inborn Errors Of Metabolism Regional And Country Analysis
.
.
.
27. Medical Foods For Inborn Errors Of Metabolism Competitive Landscape And Company Profiles
28. Medical Foods For Inborn Errors Of Metabolism Key Mergers And Acquisitions
29.Medical Foods For Inborn Errors Of Metabolism Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- BASF SE
- Abbott Laboratories Inc.
- Danone SA
- Bristol-Myers Squibb Co
- Meiji Holdings Co Ltd.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Hemolytic Anemia is a condition in which red blood cells are prematurely destructed than they can be produced by bone marrow.
When you have anemia, your blood can’t bring enough oxygen to all of your tissues and organs.
When this procedure is intruded, excess bilirubin stains other body tissues yellow.
Fatty tissues like skin, eye tissue and veins are generally influenced.
Hemoglobin Disease (Sickle Cell Anemia)
Sickle cell anemia is an inherited, acquired disease.
